We are live on !
Find out more
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
Turnover
42.78%
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.38%
10 Year Est. Return
+875.18%
AUM
$80.2B
AUM Growth
+$3.12B
(+4%)
Cap. Flow
-$3.01B
Cap. Flow % of AUM
Cap. Flow %
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
13.57%
Holding
3,665
New
834
Increased
989
Reduced
995
Closed
734
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.95% |
| 2 | Technology | 12.69% |
| 3 | Industrials | 10% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Healthcare | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2301
Sable Offshore Corp
SOC
$528M
| $667K | ﹤0.01% |
216,690
+72,848
| +51% | +$927K |
2025 Q4
2 quarters
|
|
2302
Hillman Solutions
HLMN
$1.52B
| $667K | ﹤0.01% |
78,986
-47,189
| -37% | -$375K |
2025 Q3
3 quarters
|
|
2303
Mizuho Financial
MFG
$117B
| $667K | ﹤0.01% |
69,582
+43,372
| +165% | +$390K |
2026 Q1
1 quarter
|
|
|
PBLS
2304
Parabilis Medicines Inc
PBLS
$3.5B
| $664K | ﹤0.01% |
+24,264
| New | +$670K |
2026 Q2
0 quarters
|
|
2305
Unusual Machines
UMAC
$776M
| $664K | ﹤0.01% |
29,777
+17,044
| +134% | +$316K |
2026 Q1
1 quarter
|
|
2306
Fluor
FLR
$6.27B
| $664K | ﹤0.01% |
12,672
-761,814
| -98% | -$37.3M |
2024 Q1
9 quarters
|
|
2307
Dave Inc Warrants
DAVEW
$6.87M
| $662K | ﹤0.01% |
+278,336
| New | +$244K |
2026 Q2
0 quarters
|
|
2308
Ingersoll Rand
IR
$30.7B
| $662K | ﹤0.01% |
8,079
-2,106
| -21% | -$163K |
2025 Q3
3 quarters
|
|
2309
iRhythm Holdings
IRTC
$4.07B
| $662K | ﹤0.01% |
5,563
-188,866
| -97% | -$22M |
2025 Q4
2 quarters
|
|
2310
POSCO
PKX
$15B
| $660K | ﹤0.01% |
+12,846
| New | +$880K |
2026 Q2
0 quarters
|
|
2311
T. Rowe Price
TROW
$22.2B
| $658K | ﹤0.01% |
+5,790
| New | +$592K |
2026 Q2
0 quarters
|
|
2312
VICI Properties
VICI
$26.9B
| $658K | ﹤0.01% |
24,791
-104,563
| -81% | -$2.93M |
2021 Q1
21 quarters
|
|
2313
PUT
Lemonade
LMND
$3.32B
| $657K | ﹤0.01% |
+10,100
| New | +$591K |
2026 Q2
0 quarters
|
|
2314
Nurix Therapeutics
NRIX
$2.93B
| $657K | ﹤0.01% |
+27,066
| New | +$461K |
2026 Q2
0 quarters
|
|
|
ABTC
2315
American Bitcoin Corp
ABTC
$484M
| $656K | ﹤0.01% |
64,204
+38,607
| +151% | +$591K |
2025 Q4
2 quarters
|
|
2316
Xylem
XYL
$21.2B
| $656K | ﹤0.01% |
5,547
+1,533
| +38% | +$177K |
2025 Q2
4 quarters
|
|
2317
CALL
Revolution Medicines
RVMD
$41B
| $655K | ﹤0.01% |
3,500
-46,500
| -93% | -$6.79M |
2026 Q1
1 quarter
|
|
2318
Spruce Biosciences
SPRB
$133M
| $655K | ﹤0.01% |
12,138
-27,862
| -70% | -$1.56M |
2025 Q4
2 quarters
|
|
2319
PureCycle Technologies Inc Warrant
PCTTW
| $654K | ﹤0.01% |
251,400
+196,200
| +355% | +$459K |
2026 Q1
1 quarter
|
|
2320
CALL
LyondellBasell Industries
LYB
$22.2B
| $653K | ﹤0.01% |
12,400
-5,500
| -31% | -$380K |
2026 Q1
1 quarter
|
|
2321
Stoke Therapeutics
STOK
$1.7B
| $652K | ﹤0.01% |
19,939
-3,939
| -16% | -$126K |
2025 Q4
2 quarters
|
|
2322
Equinor
EQNR
$115B
| $652K | ﹤0.01% |
+20,764
| New | +$776K |
2026 Q2
0 quarters
|
|
2323
Cincinnati Financial
CINF
$27.8B
| $650K | ﹤0.01% |
3,509
+1,180
| +51% | +$196K |
2025 Q4
2 quarters
|
|
2324
CALL
Trip.com Group
TCOM
$24.9B
| $649K | ﹤0.01% |
16,300
-13,300
| -45% | -$659K |
2025 Q3
3 quarters
|
|
2325
Chiron Real Estate Inc
XRN
$402M
| $645K | ﹤0.01% |
+17,197
| New | +$610K |
2026 Q2
0 quarters
|
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $3.01B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.